In this commentary, I offer some reflections on three of the key findings from the open-access model for medicationassisted treatment (MAT) investigated by Lynn Madden and colleagues in Connecticut, USA [1] . My perspective is from that of a MAT consumer in Australia. Madden et al.' s open-access model was able to eliminate the standard criterion of 'discharging people from treatment for continued illicit drug use' without any deleterious effects. This finding highlights the importance of measuring treatment outcomes beyond non-medical opioid use/illicit drug use. Even those who continue to use illicit drugs periodically over and above their MAT medication can achieve positive treatment outcomes. Treatment outcomes need to be measured in terms of what people are seeking from their treatment and need to be highly individualized, as each person's treatment journey is different. Moreover, where people are when they commence treatment (their life circumstances, history, other health issues, drug using status, etc.) will greatly determine what they will value and set as their treatment goals and outcomes and what they will define as 'success' [2] . In addition, in the context of the extremely high opioid overdose rates currently occurring across North America, and increasingly in other nations around the world, discharging people from MAT treatment because they continue to use illicit opioids simply serves to escalate their risk of overdose and denies them access to a treatment that has been shown to provide a protective factor in relation to opioid overdose [3] at the very time, one could argue, they need it most.
The second finding of significance from a MAT consumer perspective is that the elimination of waiting-times and the provision of immediate access to MAT services (walk-in, same day, intake, admission and dosing commencement) need not result in compromises to the level and quality of services provided. However, they rely upon services being open, flexible and willing to review the fundamental assumptions that currently underpin their service delivery models. Services need to be open to changing approaches to ensure that they are genuinely 'patient-focused' and also 'consumer-driven'. In their study of open-access treatment, Madden et al. demonstrated that 'patient-centred' approaches can produce beneficial outcomes. Research has also shown the significant additional benefits associated with direct 'consumer/service user participation' in health services, including in drug treatment settings [4] . Future studies into building the capacity of MAT services should seek to move beyond approaches that rely solely upon medical and non-medical staff to identify 'patient/client-need' and, rather, include the direct involvement of MAT service users themselves to ensure that their views and experiences are central in the planning and delivery of the services they access. Research suggests that such participatory approaches will result in the development of more attractive and accessible treatment models, thereby delivering better treatment outcomes for MAT consumers [5] .
Finally, issues of funding and affordability dominate the policy discourse in relation to the provision of MAT services in most countries, but as Madden et al. rightly point out, 'methadone maintenance is economically advantageous to society because it is associated with significantly lower utilization of emergency department and inpatient care as well as lower criminal-justice-related costs'. Why do we continue to say that we cannot (as a society) afford to fully fund MAT services for all who want and need them -or is it more a matter of making the wrong choices about how available government funding, private sector support and consumer co-payments are utilized? It is well known that affordability of treatment has a significant impact upon MAT retention [6, 7] . Research in Australia has shown that MAT dispensing fees are one of the primary reasons for involuntary discontinuation of treatment and the single biggest barrier to retention in treatment [8] . Given that most people on MAT live on very limited, fixed incomes, dispensing fees represent a considerable burden for many MAT consumers. Madden et al. ' s investigation of open-access MAT highlights that issues of cost-to consumers and to service providers-are not insurmountable. Indeed, providing accessible and affordable MAT services for consumers and covering the costs of service provision can be an exercise in building (rather than diminishing) financial sustainability and capacity for expansion. Once again, the answer lies in genuine patient-centred and consumer-driven approaches that give priority to the provision of treatment for all who want it, regardless of capacity to pay, rather than seeking to 'cost' MAT places as if they are for a privileged few.
